Steris Plc Form 8-K Summary: Acquisition of Cantel Medical
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 2, 2021, details the completion of STERIS plc's acquisition of Cantel Medical Corp. (now Cantel Medical LLC). The transaction closed on June 2, 2021, making Cantel a wholly-owned subsidiary of STERIS. The filing also addresses related debt financing and amendments to existing convertible notes.
Key Financial Metrics and Transaction Details
- Transaction Consideration: STERIS paid approximately $716.4 million in cash and issued approximately 14.3 million STERIS ordinary shares.
- Per-Share Consideration: Cantel shareholders received $16.93 in cash and 0.33787 STERIS shares for each Cantel share held.
- Debt Financing: In connection with the closing, a STERIS subsidiary borrowed $650 million under a previously announced $750 million delayed draw term loan facility. The remaining $100 million capacity was terminated.
- Use of Proceeds: Funds were used to finance the cash consideration, refinance existing Cantel indebtedness, cover transaction expenses, and support working capital.
- Convertible Notes: Cantel's 3.25% Convertible Senior Notes due 2025 were amended. They are no longer convertible into Cantel stock but will convert into cash and STERIS shares based on the merger consideration.
Material Changes
The primary material change is the consolidation of Cantel Medical into STERIS plc. Cantel's separate corporate existence ceased, and it is now a direct subsidiary. The transaction resulted in a significant increase in STERIS's debt load due to the $650 million term loan draw and the issuance of new equity. The filing does not provide comparative revenue, profit, or margin data for the current period versus the prior period, as this is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary regarding future earnings outlook. The primary risks and contingencies noted relate to the execution of the merger mechanics and the restructuring of Cantel's debt obligations. Pro forma financial information is referenced in Exhibit 99.1 but is not detailed within the text of this report.
Key Facts for Investor Verification
- Verify the total enterprise value of the acquisition by combining the $716.4 million cash payment with the market value of the 14.3 million STERIS shares issued at the time of closing.
- Review the pro forma financial information in Exhibit 99.1 to understand the impact of the $650 million new debt on STERIS's leverage ratios.
- Confirm the terms of the amended 3.25% Convertible Senior Notes to understand the conversion mechanics into STERIS shares and cash.
- Check the integration plan and expected synergies, which are not detailed in this 8-K but are critical for post-acquisition performance.